During the past decade, Abramson Cancer Center at Pennsylvania Hospital conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Abramson Cancer Center at Pennsylvania Hospital" #1 sponsor was "Radiation Therapy Oncology Group" with 2 trials, followed by "Amgen" with 1 trials sponsored, "Eli Lilly and Company" with 1 trials sponsored, "Peel Therapeutics Inc" with 1 trials sponsored and "Rain Oncology Inc" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Abramson Cancer Center at Pennsylvania Hospital" #1 collaborator was "National Cancer Institute (NCI)" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Exelixis" with 1 trials as a collaborator and "NRG Oncology" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Abramson Cancer Center at Pennsylvania Hospital" are "Prostate Cancer" (2 trials), "Advanced Solid Tumor" (1 trials), "Aggressive Fibromatosis" (1 trials), "Dedifferentiated Liposarcoma" (1 trials) and "Desmoid Tumor" (1 trials). Many other conditions were trialed in "Abramson Cancer Center at Pennsylvania Hospital" in a lesser frequency.

Most popular intervention types in "Abramson Cancer Center at Pennsylvania Hospital" are "Drug" (6 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "70.2 Gy 3D-CRT/IMRT" (1 trials), "79.2 Gy 3D-CRT/IMRT" (1 trials), "Cabozantinib" (1 trials), "Conventional 3D-CRT or IMRT" (1 trials) and "Denosumab (Cohort A)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Abramson Cancer Center at Pennsylvania Hospital" are 6 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Abramson Cancer Center at Pennsylvania Hospital". undefined are not yet recruiting, 1 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Abramson Cancer Center at Pennsylvania Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Abramson Cancer Center at Pennsylvania Hospital, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".